No single ticker was named. Biotech ETFs are one way for retail investors to get exposure. Not a recommendation.
Cash-rich zombie biotechs trigger acquisition spree
The guest argued that the depressed biotech sector is seeing a turnaround signaled by aggressive bottom-fishing acquisitions of cash-rich 'zombie' biotech firms.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day — no card required.